Baudax Bio, Inc. (BXRXQ)

0.0072 -0.0008 (-9.38%) At close: 03:09PM EDT

Baudax Bio, Inc.

490 Lapp Road
Malvern, PA 19355
United States
484 395 2440
https://www.baudaxbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Geraldine A. Henwood Ph.D.	President, CEO & Director	633.25k	N/A	1952
Mike Choi	Vice President of Financial Planning & Analysis	N/A	N/A	N/A
Ms. Natalie McAndrew	Consultant & Principle Accounting Officer	N/A	N/A	1971
Dr. Chan Kim Yong Ph.D.	Chief Scientific Officer & Director	N/A	N/A	1974

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.

Corporate governance

Baudax Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.